REG - Proteome Sciences - Launch of Single Cell Proteomics Services

Proteome SciencesAnnouncement

02/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB2669Oa&default-theme=true

RNS Number : 2669O  Proteome Sciences PLC  02 October 2023

2 October 2023

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Launch of Commercial Single Cell Proteomics Services

 Proteome Sciences plc is pleased to announce the launch of SysQuant® SCP, the
 commercial service for single cell proteomics using the power of its TMTpro™
 isobaric labelling reagents. Where more traditional approaches can measure a
 few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can
 identify more than 1,000 proteins in each study of 576 single cells and
 provides novel insights into individual cell biology and heterogeneity.
 Proteome Sciences is one of the first commercial providers of such studies
 which are expected to significantly improve the performance of drug
 development across multiple diseases including cancer, neurodegeneration,
 respiratory and cardiac health, and metabolic disorders. Whilst in its
 infancy, the field of single cell proteomics is expected to grow rapidly as
 drug developers look to integrate single cell genomic data with knowledge of
 protein changes. At the same time, the complexity of the process along with
 the need to purchase and maintain costly equipment represents a significant
 barrier to entry.

 The SysQuant® SCP pipeline generates and analyses quantitative mass
 spectrometry data to reveal subtle changes not only in individual cells but
 also within sub-populations of that same main cell type. This data will
 greatly improve understanding of the biological drivers of heterogeneity and
 evolution in the contexts of disease and response to therapy, which will offer
 new therapeutic and diagnostic targets for personalized medicine.

 Commenting on the launch of SysQuant® SCP, Dr. Ian Pike Chief Scientific
 Officer stated:

 "This is an important step for Proteome Sciences as we have adapted
 cutting-edge techniques developed in academia to make them available to the
 pharmaceutical and biotechnology industries through SysQuant® SCP. We have
 built a robust platform that will provide customers with transformational data
 enabling a deeper understanding of disease biology and how drugs are
 interacting with their targets. SysQuant® SCP  studies are highly
 complementary to our established workflows performed on larger samples and
 open up a new customer base needing  access to this valuable novel single
 cell information."

 Dr. Mariola Soehngen, Chief Executive Officer commented:

 "We are pleased to be one of the first CROs providing single cell proteomics
 to our customers. The launch of SysQuant® SCP is part of our growth strategy
 along with the opening of a US facility in San Diego. We believe that
 broadening our range of services and increasing capacity are essential as the
 wider pharmaceutical industry increasingly recognises the need to study
 changes in protein expression and function to further advance and accelerate
 the drug development process."

 

 Proteome Sciences plc
 Dr. Mariola Soehngen, Chief Executive Officer                           Tel: +44 (0)20 7043 2116

 Dr. Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer

 Abdelghani Omari, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter (Corporate Finance)                     Tel: +44 (0) 20 3328 5656

 Stefano Aquilino / Tony Quirke (Equity Sales & Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPGCPUUPWPUG